February 5, 2016
Natalia Perekhvatova, the CEO of Mitotech S.A., is invited to present at the 18th Annual BIO CEO and Investor Conference in New York City. The presentation will take place on February 9, 2016 at the Waldorf Astoria.
"We are very pleased to have been invited to this industry event", said Natalia Perekhvatova, Chief Executive Officer of Mitotech S.A. "This is a great opportunity for Mitotech to provide the investment community with an update on our drug development status."
About Mitotech S.A
Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondrial addressed antioxidants. Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.